CA
NZ
UK
AU
IND
US
…
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -43.44M | -58.77M | -14.70M | -15.48M | -170.96M |
| Net income | -43.44M | -58.77M | -14.70M | -15.48M | -171.96M |
| Selling general administrative | 15.40M | 6.69M | 1.76M | 2.24M | - |
| Gross profit | -0.01M | - | - | - | -1.12M |
| Reconciled depreciation | 0.01M | 0.00M | - | - | - |
| Ebit | -41.99M | - | -13.46M | -14.01M | -170.96M |
| Ebitda | -41.98M | -58.77M | -14.01M | -15.25M | -169.84M |
| Depreciation and amortization | 0.01M | - | - | - | 1.12M |
| Operating income | -46.15M | -55.26M | -13.46M | -14.01M | -169.82M |
| Other operating expenses | 46.15M | 55.26M | 13.46M | 14.01M | 169.82M |
| Interest expense | 1.44M | 2.70M | 0.69M | 0.23M | - |
| Net interest income | -1.44M | -2.70M | -0.69M | -0.23M | - |
| Income tax expense | - | - | - | - | 1.01M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 46.14M | 55.26M | 13.46M | 14.01M | 168.70M |
| Cost of revenue | 0.01M | - | - | - | 1.12M |
| Total other income expense net | 2.71M | -3.51M | -1.24M | -1.48M | -1.14M |
| Net income from continuing ops | -43.44M | -69.17M | -14.70M | -15.48M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 121.74M | 118.55M | 3.33M | 3.90M | 286.59M |
| Other current assets | 0.83M | 0.26M | 0.16M | 0.84M | 5.18M |
| Total liab | 42.92M | 5.24M | 48.35M | 34.17M | 61.33M |
| Total stockholder equity | 78.81M | 113.31M | -45.02M | -30.27M | 225.27M |
| Other current liab | 8.12M | 4.99M | 1.58M | 2.93M | 22.90M |
| Common stock | 0.00M | - | - | - | 0.01M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Retained earnings | -160.00M | -714.96M | -47.39M | -32.70M | -297.06M |
| Cash | 98.05M | 118.29M | 3.17M | 3.06M | 201.66M |
| Total current liabilities | 9.71M | 5.24M | 3.94M | 5.69M | 37.85M |
| Net debt | -96.61M | -118.29M | -3.17M | 0.19M | -171.59M |
| Short term debt | 0.32M | - | - | - | 6.59M |
| Short long term debt | - | 19.54M | - | - | - |
| Short long term debt total | 1.45M | - | - | 3.25M | 30.07M |
| Other stockholder equity | 238.81M | 828.40M | 2.38M | 2.42M | 522.48M |
| Total current assets | 118.81M | 118.55M | 3.33M | 3.90M | 253.35M |
| Short term investments | 19.93M | 0.00M | - | - | 46.46M |
| Net receivables | - | - | - | - | 0.05M |
| Long term debt | - | - | - | 3.25M | - |
| Accounts payable | 1.28M | 0.25M | 2.36M | 2.76M | 8.36M |
| Accumulated other comprehensive income | 0.01M | -0.14M | - | - | -0.15M |
| Non currrent assets other | 0.95M | 0.41M | - | - | 1.10M |
| Non current assets total | 2.93M | 3.56M | 0.00M | 0.00M | 33.25M |
| Capital lease obligations | 1.45M | 0.00M | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -19.52M | 0.00M | - | - | - |
| Total cashflows from investing activities | -19.72M | 95.00M | - | - | 185.98M |
| Net borrowings | 7.50M | 19.97M | 6.00M | 4.30M | - |
| Total cash from financing activities | 159.61M | 0.02M | 14.24M | 12.78M | 0.23M |
| Net income | -43.44M | -58.77M | -14.70M | -15.48M | -171.96M |
| Change in cash | -20.23M | 28.17M | 0.11M | 3.00M | 79.00M |
| Begin period cash flow | 118.29M | 90.12M | 3.06M | 0.06M | 122.66M |
| End period cash flow | 98.05M | 118.29M | 3.17M | 3.06M | 201.66M |
| Total cash from operating activities | -42.98M | -67.70M | -14.13M | -9.78M | -106.32M |
| Issuance of capital stock | 42.00M | 1.59M | 6.74M | 8.47M | - |
| Depreciation | 0.01M | 0.00M | - | - | 1.12M |
| Change to account receivables | - | 0.21M | - | - | 0.40M |
| Other cashflows from financing activities | 102.11M | - | 8.24M | 8.48M | - |
| Capital expenditures | 0.20M | 0.00M | 0.00M | 0.00M | 0.03M |
| Change in working capital | 3.43M | -25.30M | -1.09M | 3.40M | 19.35M |
| Stock based compensation | 1.94M | 0.90M | 0.15M | 0.27M | - |
| Other non cash items | -2.98M | 16.37M | 1.51M | 2.04M | 45.17M |
| Free cash flow | -43.18M | -67.70M | -14.13M | -9.78M | -106.34M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| KLRS Kalaris Therapeutics, Inc. |
-0.03 1.46% |
2.02 | - | - | - | 1.36 |
| NVO Novo Nordisk A/S |
1.99 4.95% |
42.18 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
18.28 3.44% |
549.04 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
-41.91 4.31% |
931.45 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 |
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew Oxtoby | President, CEO & Director | 1974 |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director & Co-Founder | 1968 |
| Dr. Michael Philip Dybbs Ph.D. | Co-Founder & Director | 1975 |
| Dr. Napoleone Ferrara M.D. | Independent Director & Co-Founder | 1957 |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer | 1971 |
| Ms. Liisa Ann Bayko M.B.A. | CFO & Treasurer | 1971 |
| Ms. Amy Vandekop | Interim Principal Accounting Officer & Corporate Controller | 1989 |
| Ms. Kristine Curtiss | Senior Vice President of Clinical | NA |
| Dr. Jill E. Porter Ph.D. | Senior Vice President of CMC | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+2.10%
Communication Services
+1.48%
Consumer Cyclical
+2.12%
Consumer Defensive
+1.59%
Energy
-2.52%
Financial Services
+1.11%
Financials
-6.05%
Healthcare
+2.12%
Industrials
-0.12%
Real Estate
+1.25%
Technology
-0.07%
Utilities
+0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...